{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:40:55Z","timestamp":1783438855621,"version":"3.54.6"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017H1A2A1044327"],"award-info":[{"award-number":["2017H1A2A1044327"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017M3C9A6044633"],"award-info":[{"award-number":["2017M3C9A6044633"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A5A1014560"],"award-info":[{"award-number":["2017R1A5A1014560"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018M3A9H4078701"],"award-info":[{"award-number":["2018M3A9H4078701"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1A2C3006888"],"award-info":[{"award-number":["2020R1A2C3006888"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.nano.2021.102415","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:52:36Z","timestamp":1624524756000},"page":"102415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7\/8 agonist in lung cancer model"],"prefix":"10.1016","volume":"37","author":[{"given":"Jiae","family":"Koh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Nam","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Soon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Mee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Mi","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyoung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Jun","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Taik","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2021.102415_bb0005","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nano.2021.102415_bb0010","first-page":"309","article-title":"Immunotherapy of cancer in 2012","volume":"62","author":"Kirkwood","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.nano.2021.102415_bb0015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/bfgp\/ely022","article-title":"Cancer immunotherapy for metastasis: past, present and future","volume":"18","author":"Wang","year":"2019","journal-title":"Brief Funct Genomics"},{"key":"10.1016\/j.nano.2021.102415_bb0020","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.seminoncol.2012.02.007","article-title":"Whole cell vaccines\u2014past progress and future strategies","volume":"39","author":"Keenan","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.nano.2021.102415_bb0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.nano.2021.102415_bb0030","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.nano.2021.102415_bb0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nano.2021.102415_bb0040","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T-regulatory cells: key players in tumor immune escape and angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2021.102415_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4110\/in.2020.20.e4","article-title":"Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy","volume":"20","author":"Kim","year":"2020","journal-title":"Immune Netw"},{"key":"10.1016\/j.nano.2021.102415_bb0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nano.2021.102415_bb0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"10.1016\/j.nano.2021.102415_bb0060","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000168","article-title":"Myeloid-derived suppressor cells in hematologic diseases","volume":"3","author":"Bizymi","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.nano.2021.102415_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.00165","article-title":"The engagement between MDSCs and metastases: partners in crime","volume":"10","author":"Trovato","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.nano.2021.102415_bb0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.nano.2021.102415_bb0075","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev"},{"key":"10.1016\/j.nano.2021.102415_bb0080","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3389\/fimmu.2018.00610","article-title":"Combination immunotherapy: taking cancer vaccines to the next level","volume":"8","author":"Grenier","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.nano.2021.102415_bb0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/molecules24010009","article-title":"Molecular repolarisation of tumour-associated macrophages","volume":"24","author":"van Dalen","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.nano.2021.102415_bb0090","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.4049\/jimmunol.1401572","article-title":"The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity","volume":"193","author":"Ostrand-Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2021.102415_bb0095","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.nano.2021.102415_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.csbj.2018.11.004","article-title":"Fates of CD8+ T cells in tumor microenvironment","volume":"17","author":"Maimela","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.nano.2021.102415_bb0105","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2021.102415_bb0110","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2021.102415_bb0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.nano.2021.102415_bb0120","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3389\/fphar.2019.01184","article-title":"Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nano.2021.102415_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.nano.2021.102415_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin Immunol"},{"key":"10.1016\/j.nano.2021.102415_bb0135","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1021\/acsnano.9b04207","article-title":"Lyophilizable and multifaceted toll-like receptor 7\/8 agonist-loaded nanoemulsion for the reprogramming of tumor microenvironments and enhanced cancer immunotherapy","volume":"13","author":"Kim","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2021.102415_bb0140","series-title":"Ullmann\u2019s Encycl. Ind. Chem.","article-title":"Fats and Fatty Oils","author":"Thomas","year":"2000"},{"key":"10.1016\/j.nano.2021.102415_bb0145","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.immuni.2005.10.001","article-title":"Macrophage polarization comes of age","volume":"23","author":"Mantovani","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.nano.2021.102415_bb0150","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.nano.2021.102415_bb0155","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.4049\/jimmunol.1402004","article-title":"Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells","volume":"194","author":"Wang","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2021.102415_bb0160","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fimmu.2018.00608","article-title":"Factors influencing the differentiation of human monocytic myeloid-derived suppressor cells into inflammatory macrophages","volume":"9","author":"Bayik","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.nano.2021.102415_bb0165","doi-asserted-by":"crossref","first-page":"1903242","DOI":"10.1002\/adma.201903242","article-title":"A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy","volume":"31","author":"Phuengkham","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.nano.2021.102415_bb0170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.biomaterials.2015.02.070","article-title":"Macrophage silica nanoparticle response is phenotypically dependent","volume":"53","author":"Herd","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2021.102415_bb0175","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nano.2021.102415_bb0180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.nano.2021.102415_bb0185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2021.102415_bb0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14760584.2014.851606","article-title":"Tumor lysate-loaded biodegradable microparticles as cancer vaccines","volume":"13","author":"Joshi","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.nano.2021.102415_bb0195","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.smim.2008.09.006","article-title":"Antigens for cancer immunotherapy","volume":"20","author":"Neller","year":"2008","journal-title":"Semin Immunol"},{"key":"10.1016\/j.nano.2021.102415_bb0200","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/vaccines3020344","article-title":"Whole tumor antigen vaccines: where are we?","volume":"3","author":"Chiang","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2021.102415_bb0205","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1002\/advs.201700050","article-title":"Polyelectrolyte-enrobed cancer cells in view of personalized immune-therapy","volume":"2","author":"Lybaert","year":"2017","journal-title":"Adv Sci"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963421000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963421000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:16:27Z","timestamp":1761549387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963421000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":41,"alternative-id":["S1549963421000587"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2021.102415","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7\/8 agonist in lung cancer model","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2021.102415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102415"}}